Publications And Funding

Lab Publications

Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. Cancer Discov. 2016 Sep 7. [Epub ahead of print] PMID: 27604488

Bidirectional Crosstalk Between Patient-Derived Melanoma and Cancer-Associated Fibroblasts Promotes Invasion and Proliferation.
Izar B, Joyce C, Goff S, Cho NL, Shah PM, Sharma G, Li J, Ibrahim N, Gold J, Hodi FS, Garraway LA, Novina CD, Bertagnolli MM, Yoon CH. Pigment Cell Melanoma Res. 2016 Aug 2. [Epub ahead of print] PMID: 27482935

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, Garber J, Joffe S, Lindeman N, Wagle N, Garraway LA, Van Allen EM. Genome Med. Jul 26. 8(1):79 PMID: 27460824

gkmSVM: an R package for gapped-kmer SVM.
Ghandi M, Mohammad-Noori M, Ghareghani N, Lee D, Garraway L, Beer MA. Bioinformatics. 2016 Apr 19. pii: btw203. PMID: 27153639

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Cell Rep. Apr 14. pii: S2211-1247(16)30364-3. PMID: 27149842

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA. Science 2016 Apr 8;352(6282):189-96. PMID: 27124452

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. Science 2016 Mar 11;351(6278):1214-8. PMID: 26912360

TERT promoter mutations and monoallelic activation of TERT in cancer.
Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV. Oncogenesis 2015 Dec 14;4:e176. PMID: 26657580

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors.
Kryukov GV, Bielski CM, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Garraway LA, Sweeney CJ, Taplin ME, Van Allen EM. Clin Cancer Res. 2015 Dec 2 [Epub ahead of print] PMID: 26631610

Pharmacogenomic agreement between two cancer cell line data sets.
Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Nature 2015 Dec 3;528(7580):84-7 PMID: 26570998

Genomic correlates of response to CTLA4 blockade in metastatic melanoma.
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Science. 2015 Sep 10 [Epub ahead of print] PMID: 26359337

Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors.
Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA. Mol Cancer Ther. 2015 Sep 8 [Epub ahead of print] PMID: 26351322

A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. Cancer Cell 2015 Mar 9;27(3):397-408. PMID: 25759024

RNF43 is frequently mutated in colorectal and endometrial cancers
Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, Garraway LA. Nat Genet. 2014 Dec;46(12):1264-6. PMID: 25344691

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors
Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. Cancer Res. 2014 Dec 1;74(23):7079-89. PMID: 25320010

Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH.N Engl J Med. 2014 Oct 9;371(15):1426-33. PMID: 25295501

Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer
Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Privé GG, Carr SA, Garraway LA. Science 2014 Oct 3;346(6205):85-9 PMID: 25278611

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos JP, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE. Cancer Discov. 2014 Oct;4(10):1140-53.PMID: 25096233

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. Cancer Discov. 2014 Jul;4(7):816-27. PMID: 24771846

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA. Nat Med. 2014 Jun;20(6):682-8 PMID: 24836576

A Notch for noncoding RNA in melanoma
Garraway LA. N Engl J Med. 2014 May 15;370(20):1950-1 PMID: 24827041

A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein
Pop MS, Stransky N, Garvie CW, Theurillat JP, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA. Mol Cancer Ther. 2014 Jun;13(6):1492-502 PMID: 24737027

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Cancer Discov. 2014 May;4(5):546-53 PMID: 24625776

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7 PMID: 24366412

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. Cancer Discov. Cancer Discov. 2014 Jan;4(1):61-8 PMID: 24265154

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D Cancer Discov 2014 Jan;4(1):94-109 PMID: 24265153

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. Nature 2013 Dec 5;504(7478):138-42 PMID: 24185007

C-RAF mutations confer resistance to RAF inhibitors
Antony R, Emery CM, Sawyer AM, Garraway LA. Cancer Res. 2013 Aug 1;73(15):4840-51 PMID: 23737487

Punctuated evolution of prostate cancer genomes
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, Macdonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. Cell 2013 Apr 25;153(3):666-77 PMID: 23622249

Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway LA J Clin Oncol. 2013 May 20;31(15):1806-14 PMID: 23589557

Precision Oncology: An Overview
Garraway LA, Verwey J, Ballman K.J Clin Oncol. 2013 May 20;31(15):1803-5 PMID: 23589545

Lessons from the cancer genome
Garraway LA, Lander ES. Cell 2013 Mar 28;153(1):17-37 PMID: 23540688

Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Science 2013 Feb 22;339(6122):957-9 PMID: 23348506

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. Cancer Discov. 2013 Mar;3(3):350-62 PMID: 23288408

Concordance and Discordance in Tumor Genomic Profiling
Garraway LA. JCO. 2012 Aug 20;30(24):2937-9. PMID: 22826272

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones
Konieczkowski DJ, Garraway LA. Cell Research. 2012 Jul 31. doi: 10.1038/cr.2012.115.PMID:22847744

A Landscape of Driver Mutations in Melanoma
Hodis E, Watson I, Kryukov GV, Arold S, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, DiCara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachencko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DSB, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA*, Chin L*. Cell 2012 July 20;150:251-263. PMID:22817889

The genomic landscape of prostate cancer
Baca SC, Garraway LA. Front Endocrinol. 2012 May 16;3:69 PMID: 22649426

Melanoma genome sequencing reveals frequent PREX2 mutations
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA.Nature 2012 May 9;485(7399):502-6.PMID: 22622578

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, Macdonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Nat Genet. 2012 May 20;44(6):685-9 PMID: 22610119

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R , and Garraway LA. Nature. 2012 March 29;483(7391):603-607 PMID: 22460905

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Pochanard P, Ducar M, Van Hummelen P, MacConaill LE, Hahn WC, Meyerson M, Gabriel SB, and Garraway LA. Cancer Discovery 2012 Jan; 2(1):82-93.PMID: 22585170

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, Macconaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA. J Clin Oncol. 2012 Jan 20;30(3):316-21 PMID: 22067401

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence M, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, GuiducciC, Onofrio R, Parkin P, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. Science. 2011 Aug 26;333(6046):1157-60 PMID: 21798893

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. J Clin Oncol. 2011 Aug 1;29(22):3085-96 PMID: 21383288

The genomic complexity of primary human prostate cancer
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, Macdonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. Nature. 2011 Feb 10;470(7333):214-20 PMID: 21307934

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Nature. 2010 Dec 16;468(7326):968-72 PMID: 21107320

AKT Signaling in Physiology and Disease
Vasudevan KM, Garraway LA. Curr Top Microbiol Immunol. 2011; 347:105-33 PMID: 20549472

Integrative analysis of the melanoma transcriptome
Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Genome Res. 2010 Apr;20(4):413-27. PMID: 20179022

An oncogenic role for ETV1 in melanoma
Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. Cancer Res. 2010; 70(5):2075-84. PMID: 20160028

Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts
Levin JZ*, Berger MF*, Adiconis X, Rogov P, Melnikov A, Fennell T, Nusbaum C, Garraway LA, Gnirke A. Genome Biol. 2009; 10(10):R115. PMID: 19835606

AKT signaling in physiology and disease
Vasudevan, K.M., Garraway LA. Current Topics in Microbiology and Immunology. In press. Book Chapter.

Stepping on the GAS: a brake pedal for melanoma metastasis?
Linja M, Garraway LA. Pigment Cell Melanoma Res. 2009 Feb; 22(1):8-9. PMID: 19154234

Applications of genomics in melanoma oncogene discovery
Berger MF, Garraway LA. Hematol Oncol Clin North Am. 2009 Jun; 23(3):397-414, vii. Review. PMID: 19464593

p85 Associates with unphosphorylated PTEN and the PTEN-associated complex
Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. Mol Cell Biol. 2009 Oct; 29(19):5377-88. PMID: 19635806

MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci USA. 2009 Dec 1; 106(48):20411-6. Epub 2009 Nov 13. PMID: 19915144

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer
Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., Hennessy, B.T., Tseng, H., Pochanard, P., Kim, S.Y., Dunn, I.F., Schinzel, A.C., McNear, C.J., Sandy, P., Hoersch, S., Sheng, Q., Gupta, P.B., Boehm, J.S., Reiling, J.H., Silver, S., Lu, Y., Stemke-Hale, K., Dutta, B., Joy, C., Sahin, A.A., Gonzalez-Angulo, A.M., Lluch, A., Rameh, L.E., Jacks, T., Root, D.E., Lander, E.S., Mills, G.B., Hahn, W.C., Sellers, W.R., Garraway, L.A. Cancer Cell. 2009 Jul 7; 16(1):21-32. PMID: 19573809

Modeling genomic diversity and tumor dependency in malignant melanoma
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Cancer Res. 2008; 68(3):664-73. PMID: 18245465

High-throughput oncogene mutation profiling in human cancer
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. Nature Genetics. 2007; 39(3):347-351. PMID: 17293865

Lineage dependency and lineage-survival oncogenes in human cancer
Garraway LA, Sellers WR. Nat Rev Cancer. 2006 Aug; 6(8):593-602. Review. PMID: 16862190

From integrated genomics to tumor lineage dependency
Garraway LA, Sellers WR. Cancer Res. 2006 Mar 1; 66(5):2506-8. Review. PMID: 16510564

"Lineage addiction" in human cancer: lessons from integrated genomics
Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. Cold Spring Harb Symp Quant Biol. 2005; 70:25-34. PMID: 16869735

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Nature. 2005 Jul 7; 436(7047):117-22. PMID: 16001072

PI Publications

Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies.
Dang M, Henderson RE, Garraway LA, Zon LI. Dis Model Mech. 2016 Jul 1;9(7):811-20.

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH; CSER Consortium. Am J Hum Genet. 2016 Jul 7;99(1):246.

Integrated genetic and pharmacologic interrogation of rare cancers.
Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS. Nat Commun. 2016 Jun 22;7:11987.

Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.
Louissaint A Jr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morin R, Morgan EA, Neuberg DS, South ST, Harris MH, Hasserjian RP, Hochberg EP, Garraway LA, Harris NL, Weinstock DM. Blood 2016 Aug 25;128(8):1093-100.

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. JAMA Oncol. 2016 Aug 1;2(8):1094-6.

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, Kryukov G, Cowley GS, Garraway LA, Stegmaier K, Roberts CW, Golub TR, Meyerson M, Root DE, Tsherniak A, Hahn WC. Cancer Discov. 2016 Aug;6(8):914-29.

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. JAMA Oncol. 2016 Aug 1;2(8):1094-6.

Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting.
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, Kryukov G, Cowley GS, Garraway LA, Stegmaier K, Roberts CW, Golub TR, Meyerson M, Root DE, Tsherniak A, Hahn WC. Cancer Discov. 2016 Jun 3. pii: CD-16-0154.

Distinct Genetic Profiles of Extracranial and Intracranial Acral Melanoma Metastases.
Sharma G, Lian CG, Lin WM, Amin-Mansour A, Jané-Valbuena J, Garraway L, Bao W, Yoon CH, Ibrahim N. J Cutan Pathol. 2016 Jun 2.

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato AC, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M. Cancer Cell. 2016 May 24.

A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine.
Allen EM, Robinson D, Morrissey C, Pritchard C, Imamovic A, Carter S, Rosenberg M, McKenna A, Wu YM, Cao X, Chinnaiyan A, Garraway L, Nelson PS. Oncotarget. 2016 May 5.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. JAMA Oncol. 2016 Apr 28.

Characterizing genomic alterations in cancer by complementary functional associations.
Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, Ghandi M, Greulich H, Vazquez F, Weir BA, Van Allen EM, Tsherniak A, Shao DD, Zack TI, Noble M, Getz G, Beroukhim R, Garraway LA, Ardakani M, Romualdi C, Sales G, Barbie DA, Boehm JS, Hahn WC, Mesirov JP, Tamayo P. Nat Biotechnol. 2016 May;34(5):539-46.

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.
Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, Taylor BR, Crenshaw A, Gould JZ, Tamayo P, Weir BA, Tsherniak A, Wong B, Garraway LA, Shamji AF, Palmer MA, Foley MA, Winckler W, Schreiber SL, Kung AL, Golub TR. Nat Biotechnol. 2016 Apr;34(4):419-23.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C. Science. 2016 Mar 3 [Epub ahead of print].

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.
Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, Taylor BR, Crenshaw A, Gould JZ, Tamayo P, Weir BA, Tsherniak A, Wong B, Garraway LA, Shamji AF, Palmer MA, Foley MA, Winckler W, Schreiber SL, Kung AL, Golub TR. Nat Biotechnol. 2016 Feb 29 [Epub ahead of print].

Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L. Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Nat Med. 2016 Mar;22(3):298-305.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. JEur J Cancer. 2015 Dec;51(18):2792-9.

Rapid Intraoperative Molecular Characterization of Glioma.
Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG 2nd, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M. JAMA Oncol. 2015 Aug 1;1(5):662-7.

Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E,Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S.JAMA Oncol. 2015 Aug 1;1(5):653-61.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. JAMA Oncol. 2015 May 1;1(2):238-44.

Genomic Classification of Cutaneous Melanoma.
Cancer Genome Atlas Network. Cell. 2015 Jun 18;161(7):1681-96.

Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai TC, Lydon C, Mach S, Wong JA, Rabin AR, Helmkamp J, Sholl LM, Carter SL, Oxnard GR, Janne PA, Getz G, Lindeman NI, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Cancer Immunol Res. 2015 May 26. [Epub ahead of print]

Integrative clinical genomics of advanced prostate cancer.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Cell 2015 May 21;161(5):1215-28.

Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation.
Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, Struhl K. Proc Natl Acad Sci U S A. 2015 May 5;112(18):5708-13.

PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. Cancer Res. 2015 Feb 11. [Epub ahead of print]

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB. Cancer Discov. 2014 2015 Apr;5(4):358-67.

Genetic modifiers of EGFR dependence in non-small cell lung cancer
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18661-6.

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73.

Integrated genomic characterization of papillary thyroid carcinoma
Cancer Genome Atlas Research Network. Cell 2014 Oct 23;159(3):676-90.

Unraveling the clonal hierarchy of somatic genomic aberrations
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera J, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. J Genome Biol.2014 Aug 26;15(8):439.

Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI. J Mol Diagn. 2014 Aug 22. [Epub ahead of print]

Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, Iafrate AJ, Garraway LA, Hornicek FJ, Duan Z. PLoS One 2014 Jul 1;9(7):e101283.

Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. Nat Biotechnol. 2014 Jul;32(7):644-52.

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. Cancer Med. 2014 May 21. [Epub ahead of print]

ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CW. Nat Med. 2014 Mar;20(3):251-4.

Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection.
Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR. Mol Cancer Res. 2014 Mar 28. [Epub ahead of print].

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1114-9.

Discovery and saturation analysis of cancer genes across 21 tumour types.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Nature 2014 Jan 23;505(7484):495-501.

Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair.
Polak P, Lawrence MS, Haugen E, Stoletzki N, Stojanov P, Thurman RE, Garraway LA, Mirkin S, Getz G, Stamatoyannopoulos JA, Sunyaev SR. Nat Biotechnol. 2013 Dec 15.[Epub ahead of print]

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. Invest New Drugs. 2013 Nov 16. [Epub ahead of print]

Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium
Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, Wagle N, Rehm HL, Dechene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, Evans JP, Jarvik GP. Genet Med. 2013 Nov;15(11):860-7

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Nat Med. 2013 Oct 27. [Epub ahead of print]

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E 3rd, Wei L, Ma J, Easton J, Yu Z, Debeaumount R, Gibaja V, Venkatesan K, Schlegel R, Sellers WR, Keen N, Liu J, Caponigro G, Barretina J, Cooke VG, Mullighan C, Carr SA, Downing JR, Garraway LA, Stegmeier F. Nat Genet. 2013 Sep 29. [Epub ahead of print].

A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record
Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, Hindorff LA, Jarvik G, Karavite D, Lebo M, Plon SE, Van Allen E, Weck KE, White PS, Yang Y. Genet Med. 2013 Oct;15(10):824-832.

Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency
Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, Jang SJ, Osarogiagbon RU, Hahn WC, Meyerson M, Garraway LA, Macconaill LE. PLoS One 2013 Sep 16;8(9):e74950.

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules
Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL. Cell 2013 Aug 29;154(5):1151-61.

Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, Dicara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Nature 2013 Jun 16. doi: 10.1038/nature12213. [Epub ahead of print]

Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers
Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, Garraway LA, Tamayo P, Mesirov JP, Beroukhim R, Hahn WC. J Cancer Discov. 2013 Jun 13. [Epub ahead of print]

Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients
Barbieri CE, Sboner A, Rubin MA, Garraway LA. J Pathol 2013 May 9. doi: 10.1002/path.4208.

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala RR, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Ng PK, Garraway LA, Hammerman P, Mills GB, Grandis JR. Cancer Discov. 2013 Apr 25. [Epub ahead of print]

Attitudes of patients with cancer about personalized medicine and somatic genetic testing
Gray SW, Hicks-Courant K, Lathan CS, Garraway L, Park ER, Weeks JC J Oncol Pract. 2012 Nov;8(6):329-35, 2 p following 335.

Epigenomic alterations in localized and advanced prostate cancer
Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O. Neoplasia 2013 Apr;15(4):373-83.

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. Proc Natl Acad Sci USA. 2013 Feb 27. [Epub ahead of print]

Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes
Demichelis F, Garraway LA, Rubin MA.Cancer Cell. 2013 Feb 11;23(2):133-5.

ATARiS: Computational quantification of gene suppression phenotypes from multi-sample RNAi screens
Shao DD, Tsherniak A, Gopal S, Weir BA, Tamayo P, Stransky N, Schumacher SE, Zack TI, Beroukhim R, Garraway LA, Margolin AA, Root DE, Hahn WC, Mesirov JP. Genome Res. 2012 Dec 26. [Epub ahead of print]

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
Kieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA. Pediatr Blood Cancer. 2012 Sep 19; [Epub ahead of print]

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M. Cell. 2012 Sep 14;150(6):1107-20.

Whole-genome sequencing and cancer therapy: is too much ever enough?
Garraway LA, Baselga J. Cancer Discov. 2012 Sep;2(9):766-8.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB, Lee JE, Macconaill LE, Palescandolo E, Van Hummelen P, Adams SM, Deangelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK. Invest Ophthalmol Vis Sci. 012 Sep 13. [Epub ahead of print]

Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA. Cancer Discov. 2012 Sep 7. [Epub ahead of print]

Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Mol Cancer Ther. 2012 Aug 9. [Epub ahead of print]

Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. Nature 2012 Jun 20;486(7403):405-9.

Melanoma: from mutations to medicine
Tsao H, Chin L, Garraway LA, Fisher DE. Genes Dev. 2012 Jun 1;26(11):1131-55.

MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, Botvinnik OB, Mesirov JP, Hahn WC, Root DE, Garraway LA, Sabatini DM. Sci Signal. 2012 May 15;5(224):rs4.

Circumventing cancer drug resistance in the era of personalized medicine
Garraway LA, Jänne PA. Cancer Discovery. 2012 Mar;2(3):214-26.

High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, Garraway L, Duan Z. Cancer 2012 Jun 1;118(11):2905-14.

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, Depinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M. Nat Genet. 2011 Sep 4;43(10):964-8.

Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients
Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. J Invest Dermatol. 2012 Jan;132(1):188-97.

Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas
Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL. J Mol Diagn. 2011 Nov;13(6):669-77.

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM, Sabatini DM. Nature. 2011 Aug 18;476(7360):346-50.

Nuclear factor I/B is an oncogene in small cell lung cancer
Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. Genes Dev. 2011 Jul 15;25(14):1470-5.

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R, Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC. Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12372-7.

Initial genome sequencing and analysis of multiple myeloma
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Nature. 2011 Mar 24;471(7339):467-72.

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI. Nature. 2011 Mar 24;471(7339):513-7.

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors towards inhibition of the RAS/RAF/MEK signaling cascade
Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. Blood. 2011 Feb 24;117(8):2433-40.

An Integrated Approach to Uncover Drivers of Cancer
Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D. Cell. 2010 Dec 10;143(6):1005-17.

Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma
Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, Granter SR, Turley SJ, Fisher DE, Novina CD. Mol Cell. 2010 Dec 10;40(5):841-9.

Clinical Implications of the Cancer Genome
Macconaill LE, Garraway LA. J Clin Oncol. 2010 Dec;28(35):5219-28.

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S. Nature Genetics. 2010 Aug;42(8):715-21.

On or off target: mutations, models, and predictions
Garraway LA, Hahn WC. Sci Transl Med. 2010 Jun 9;2(35):35ps28.

Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very G, Vergilio JA, Degar BA, Macconaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Blood. 2010 Sept;116(11):1919-23

The landscape of somatic copy-number alteration across multiple human cancer types
Beroukhim R*, Mermel CH*, Porter D, Wei G, Raychaudhuri S, (40 authors) Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. Nature. 2010, Feb;463(7283):899-905.

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set
Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Mol Cancer Ther. 2010 Feb;9(2):257-67.

Profiling critical cancer gene mutations in clinical tumor samples
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA. PLoS One. 2009 Nov 18; 4(11):e7887.

Oncogenic activating mutations are associated with local copy gain
Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z, Seshagiri S, Stern HM, Waring P, Garraway LA, Chant J, Stokoe D, Cavet G. Mol Cancer Res. 2009 Aug; 7(8):1244-52.

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, Heynck S, Beroukhim R, Lin W, Winckler W, Shah K, LaFramboise T, Moriarty WF, Hanna M, Tolosi L, Rahnenführer J, Verhaak R, Chiang D, Getz G, Hellmich M, Wolf J, Girard L, Peyton M, Weir BA, Chen TH, Greulich H, Barretina J, Shapiro GI, Garraway LA, Gazdar AF, Minna JD, Meyerson M, Wong KK, Thomas RK. J Clin Invest. 2009 Jun; 119(6):1727-40.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK. Cancer Res. 2009 Apr 15; 69(8):3256-61.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R. Proc Natl Acad Sci USA. 2009 Mar 24; 106(12):4834-9.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Cancer Genome Atlas Research Network. Nature. 2008 Oct 23;455(7216):1061-8.

Major copy proportion analysis of tumor samples using SNP arrays
Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M. BMC Bioinformatics. 2008 Apr 21; 9:204.

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines
Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. Nucleic Acids Res. 2008; 36(7):2446-56.

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Proc Natl Acad Sci USA. 2007 Dec 11; 104(50):20007-12.

Characterizing the cancer genome in lung adenocarcinoma
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Nature. 2007 Dec 6; 450(7171):893-8.

A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome
Hill AD, Chang BS, Hill RS, Garraway LA, Bodell A, Sellers WR, Walsh CA. Am J Med Genet A. 2007 Aug 1; 143A(15):1692-8.

Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. Cell. 2007 Jun 15; 129(6):1065-79.

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models
Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK. Cancer Res. 2007 May 15; 67(10):4933-9.

Malignant melanoma: genetics and therapeutics in the genomic era
Chin L, Garraway LA, Fisher DE. Genes Dev. 2006 Aug 15; 20(16):2149-82. Review.

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M. Nat Med. 2006 Jul;12(7):852-5.

Androgen-dependent regulation of Her-2/neu in prostate cancer cells
Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Cancer Res. 2006 Jun 1; 66(11):5723-8.

BRAF mutation predicts sensitivity to MEK inhibition
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Nature. 2006;439(7074):358-62.

Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays
Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, Li C. PLoS Comput Biol. 2006 May; 2(5):e41.

BRAF mutation predicts sensitivity to MEK inhibition
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Nature. 2006 Jan 19; 439(7074):358-62.

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M. Cancer Res. 2005;65(13):5561-70.

Intermediate basal cells of the prostate: in vitro and in vivo characterization
Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Prostate. 2003 May 15; 55(3):206-18.

p63 is a prostate basal cell marker and is required for prostate development
Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. Am J Pathol. 2000;157(6):1769-75.

Funding

Howard Hughes Medical Institute
Melanoma Research Alliance
Melanoma Research Foundation
National Cancer Institute
Robert Wood Johnson Foundation
The Burroughs-Wellcome Fund
The National Institute for Human Genome
Novartis Institute for Biomedical Research
Prostate Cancer Foundation
Adelson Medical Research Foundation
Dana Farber/Harvard Cancer Center
Starr Cancer Consortium
Harry J. Lloyd Charitable Trust
US Department of Defense